Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

Sanofi India Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 18.001116
debtToEquity 2.376000
earningsGrowth -0.141000
revenueGrowth -0.119000
grossMargins 0.490360
operatingMargins 0.283290
trailingEps 134.610000
forwardEps 179.066670

Sanofi India Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
Sanofi India Limited's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
SANOFI's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
With SANOFI's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in SANOFI's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

The current valuation of SANOFI against its projections does not reveal significant risks or opportunities. This neutral assessment implies a stable market, where investors may prefer to maintain their positions until future trends become clearer.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


Analysts have provided a mixed outlook for SANOFI, offering no definitive buy or sell recommendations. This lack of consensus suggests that investors should proceed with caution and consider a variety of market indicators before making decisions, as the stock's future direction remains uncertain.